"Designing Growth Strategies is in our DNA"
The global glaucoma therapeutics market size was USD 6.59 billion in 2019 and is projected to reach USD 11.05 billion by 2027, exhibiting a CAGR of 6.1% during the forecast period.
Glaucoma is one of the most common ophthalmic disorders that are encountered in secondary and primary care facilities and the third leading cause of blindness among the population. According to BrightFocus Foundation, glaucoma is prevalent in 3 million individuals in the U.S. and out of those, 2.7 million are aged more than 40 years. This slow progressing disorder is caused due to structural changes in the optical nerve causing blindness or varying levels of visual loss. The increasing pool of geriatric population and improving diagnostic tools to detect glaucoma are aiding the glaucoma therapeutics market growth.
COVID-19 Pandemic: Postponement of Glaucoma Surgeries Worldwide to Impact Growth
Glaucoma is characterized as a slow progressing eye disorder. Due to this characteristic, various government healthcare facilities have categorized glaucoma surgery as elective and all surgeries related to this disorder will be postponed until the coronavirus situation comes under control. According to the instructions from the American Academy of Ophthalmology, glaucoma and other non-critical ophthalmic surgeries should be safely postponed, particularly in elderly patients with comorbidities. This has led to an increase in the consumption of therapeutic products to delay the progression of glaucoma. The government authorities have also urged the public to stock up on medicines so that it does not impact on the availability of drugs if the COVID-19 scenario worsens over the course of time.
Request a Free sample to learn more about this report.
A Shift towards Adoption of Prostaglandin Analogs is a Prominent Trend
An increase in the research in prostaglandin analogs have caused a shift towards the adoption of this drug class among individuals suffering from glaucoma. The drug class promises better efficiency and lower side effects, as compared to the other treatment options and therapeutic products. However, innovations in glaucoma devices could negatively impact this trend.
Rising Prevalence of Glaucoma to Bolster Market Growth
There is currently an increasing prevalence of glaucoma among the elderly population. The increasing screen time of gadgets such as laptops and smart phones among the geriatric population is further aiding in the rising incidence of glaucoma. According to the International Agency of the Prevention of Blindness, in 2018, around 1.9% of the U.S. population above 40 years of age has glaucoma. The Agency also estimates that by 2020, around 80 million people will suffer from glaucoma globally.
Increasing Products under Pipeline and Recent Product Launches to Accelerate Growth
There are numerous pipeline products under development for the treatment of glaucoma. Aerie Pharmaceuticals Inc., on May 15, 2019 announced the submission of a New Drug Application (NDA) to the U.S. FDA for Roclatan, a fixed dose combination for glaucoma therapy. Data from clinicaltrials.gov shows that there are currently around 70 ongoing studies related to glaucoma therapeutics as of 2020.
Drug Recalls by Major Players is Projected to Hinder Demand for Glaucoma Therapeutics
Drug recalls for glaucoma treatment from major players could have a predominant impact on the market growth. For instance, Allergan had to recall one lot of Lumigan and seven lots of Combigan due to failure to meet the regulatory standards and impurity qualifications to be distributed to the patients. Regulatory recalls of such products could generate skepticism and fear among the healthcare professionals and patients over drugs marketed for glaucoma treatment. Combined with this, devices that promise long term benefits, efficacy, and lower side effects could impact the adoption of therapeutics in this market.
To know how our report can help streamline your business, Speak to Analyst
Prostaglandins Analogs Segment to Hold Highest Share Owing to Its Ability to Lower Intraocular Pressure
On the basis of drug class, the market is categorized into beta blockers, prostaglandins analogs, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogs segment held the highest glaucoma therapeutics market share in 2019 owing to its efficacy to reduce intraocular pressure (IOP) and few side effects in comparison with the other therapies. The prostaglandins segment is further categorized into latanoprost, bimatoprost, travoprost, and others.
Combination drugs are also an upcoming therapy type to treat complicated and fast progressing glaucoma in rare cases.
Open Angle Glaucoma Dominated in 2019 Backed by High Prevalence of This Disorder
Based on disease indication, the market is segmented into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment dominated the market in 2019 and is estimated to maintain its position over the forecast duration. This is attributed to the high prevalence of the disorder, as compared to the other types of glaucoma. Additionally, majority of the glaucoma therapeutic drugs currently available are indicated to treat open angle glaucoma making it the leading segment in the category.
Hospital Pharmacy Segment to Register a Higher CAGR over the Forecast Duration
In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is projected to have the highest share in the market during the forecast period. However, the highest growth is estimated to be recorded by the retail pharmacy segment. An increasing preference of treatments in outpatient settings among the elderly population is anticipated to drive the growth of the retail pharmacy segment in the market.
North America Glaucoma Therapeutics Market Size, 2019 (USD Million)
To get more information on the regional analysis of this market, Request a Free sample
In terms of market value, North America generated a revenue of USD 2518.31 million in 2019. Well-equipped hospital infrastructure for the diagnosis of glaucoma and efficient treatment framework are some of the major factors for the dominance of North America in this market. Since, the disorder is slow progressing, efficient diagnostic equipment allows its timely detection. In Europe, the favorable reimbursement scenario is estimated to drive the adoption of glaucoma therapeutics. The National Health Services (NHS) of the U.K. has included glaucoma therapeutics under the approved subsidized therapeutic products for the use of its citizens.
On the other hand, Asia Pacific is estimated to experience the highest growth in the market owing to the increasing geriatric population in countries such as China and Japan. According to the World Bank, around 28% of Japan’s population is over 65 years and above. Lastly, the market in Latin America and the Middle East and Africa is considerably smaller owing to the limited availability of glaucoma diagnostic tools and lower awareness of the disorder.
Novartis AG and Allergan Hold Maximum Share Stoked by New Product Developments
The current scenario is fragmented with various key players operating in the market at a global level. The maximum share was held by Novartis AG and Allergan in terms of value. These two companies are focused on the manufacturing and distribution of prostaglandin analogues Travatan and Lumigan, respectively. A strong focus on new product developments and mergers and partnerships are some of the vital strategies adopted by the key players to maintain their dominance in the market. The other key players in the market include Merck & Co., Pfizer, Inc., Teva Pharmaceutical Industries, Bausch and Lomb Incorporated, Inotek Pharmaceuticals, Aerie Pharmaceutical Industry, and other players.
An Infographic Representation of Glaucoma Therapeutics Market
To get information on various segments, share your queries with us
The glaucoma therapeutics market research report provides a detailed industry analysis of the market and focuses on the key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends, market analysis, and highlights key global industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth rate of the advanced market for glaucoma therapeutics over the recent years.
To gain extensive insights into the market, Request for Customization
Value (USD billion)
By Drug Class
By Disease Indication
By Distribution Channel
Fortune Business Insights says that the global glaucoma therapeutics market size was USD 6.59 billion in 2019 and is projected to reach USD 11.05 billion by 2027.
In 2019, the North America value stood at USD 2518.31 million.
The market will exhibit a stunning growth of 6.1% in the forecast period (2020-2027).
The prostaglandins analogs segment is expected to be the leading segment in this market during the forecast period.
The rising prevalence of glaucoma is the key factor driving the growth of the market.
Novartis AG, Pfizer, Inc., and AbbVie Inc. are the major players in the global market.
North America dominated the market in terms of share in 2019.
The launch of new products by market players are expected to drive the adoption of glaucoma therapeutics.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry